The host of threats to the integrity of co-pay assistance programs has grown increasingly more diverse over time. The combination of government, legal, and regulatory provisions affecting how manufacturer programs can be operated, along with market activity and the advent of ill-intentioned bad actors, has created a risk environment around co-pay assistance that requires a holistic and multi-faceted approach to safeguarding program integrity and ensuring compliance.
This piece will examine many of the specific risks facing manufacturer programs today and outline a framework for pharmaceutical manufacturers to mitigate those risks to best ensure uninterrupted patient access and affordability support.
